Spatial Biology Market Report - Fourth Edition: 2026-2031

This report provides an overview of the spatial biology market from 2026 to 2031. The spatial biology market, as defined in this report, is comprised of revenue from instruments and reagents sold to academic, biopharma, CRO / reference lab, and clinical customers. This market is moderately consolidated today, with top vendors including 10x Genomics, Bruker, Quanterix, and Bio-Techne expected to retain majority share of the market through 2031, however, multiple other mid-sized and smaller-sized players (e.g., Leica Microsystems, NeoGenomics, and Vizgen) are poised to capture share as the market grows and evolves.

For this report, we leverage a combination of secondary research (e.g., analysis of quarterly and annual reports, earnings call transcripts, clinical trials, congress abstracts, company websites, etc.) and primary research (e.g., 26 interviews with key spatial biology stakeholders from academia, biopharma, and leading specialty CROs; 76 survey respondents across academia, biopharma, and leading specialty CROs) to assess the current and expected future adoption and utilization of spatial biology tools and technologies, and to characterize the key market dynamics. From our research and analysis, we estimate that the spatial biology market is expected to reach ~$1.14B in 2026 and is expected to grow 17% p.a. in the next 5 years, to reach ~$2.46B by 2031.* Our analysis indicates promising clinical activity and continued resilience in academic research, with continued adoption across customer types, particularly for larger-scale clinical trial applications, as clinical utilization expands in the out years.

Foreach of the subsegments analyzed, we present forecasted data from 2026-2031. In addition, we detail market drivers (e.g., the value of AI-enabled data analysis) and moderators (e.g., multi-omic feasibility), market trends (e.g., new platforms optimized for throughput), a high-level customer breakdown (academia, large pharma, small pharma, CROs), and offer key information on top competitors. All analyses are based on publicly reported data and DeciBio research and analysis.**

‍

*We do believe that uncertainty to these forecasts exist, considering that the field is relatively young and pivotal developments may occur within the forecasted period that could determine future adoption of the technology; ** Disclaimer: Some of the companies listed in this report may be DeciBio Consulting clients and customers

‍

Report Scope

Technologies and Revenues Included*:

• Spatial Biology - the study of biology and pathophysiology in which the spatial context of the analytes is taken into consideration (including both single-and multiplex spatial analyses)
• Technology classes which are designed to profile and analyze multiplex biomarkers in situ including includes mIF, mIHC, digital-spatial profiling, multiplex FISH, and imaging mass cytometry
• Instrument and reagent revenues associated with the purchase of spatial biology platforms or reagents / kits used to run the assays, as well as service revenues associated with wet-lab processing of spatial slides or image analysis (e.g., by CROs / Reference Labs) ‍
• Sales of products and services to academic, biotech / pharmaceutical companies, CRO, and clinical customers including both therapeutic companies and diagnostic / analytical tools companies

‍

Technologies and Revenues Excluded:

• Digital pathology / image analysis in which automated image analysis, algorithms, or pathologist-supported software is used to perform whole slide image analysis that does not assess the spatial context of a marker(s) within a tissue, cell, or in relation to other markers
• Service revenue related to CDx development‍
• Histology testing without spatial analyses including multiplex assays which analyze presence or intensity of analytes only

‍

*Note: Revenues from Castle Biosciences' TissueCypher test were included in this edition of the report, as the scope was expanded to encompass spatial analyses performed on images capture on digital pathology slide scanners

‍

Segmentations Covered in Market Analysis:

‍

Customer:

• Academia
• Large Biopharma
• Small Biopharma
• CRO / Reference Labs

Products / Services:

• Instruments
• Reagents
• Services
• Image Analysis Services

Technology:

• Proteomics - mIHC
• Proteomics - mIF
• Spatial Transcriptomics
• Other

Plex Level:

• 2-3 Plex
• 4-8 Plex
• 9-20 Plex
• 20+ Plex

Analyte:

• Protein
• RNA
• Other

Application:

• Basic / Discovery Research
• Translational / Clinical Research
• Routine Clinical Diagnostic

Therapeutic Area:

• Oncology
• Immuno-oncology
• Neuroscience
• Infectious Disease
• Cardiology
• Other

Competitors (grouped into tiers):

• 10x Genomics
• Bio-Techne
• Bruker
• Leica Microsystems
• NeoGenomics
• Quanterix
• Standard Biotools
• Vizgen
• Other

Geography:

• United States
• Europe
• Rest of World

Companies Profiled:

• 10x Genomics
• Bio-Techne
• Bruker
• Leica Microsystems
• NeoGenomics
• Quanterix
• Standard BioTools
• Vizgen